<DOC>
	<DOCNO>NCT01984541</DOCNO>
	<brief_summary>The objective study determine biological activity Artemisia vulgaris allergen extract histamine equivalent unit ( HEP ) unit , order use in-house reference preparation ( IHRP ) .</brief_summary>
	<brief_title>To Determine Minimum Amount Artemisia Vulgaris Allergen Extract Producing Positive Skin Reaction .</brief_title>
	<detailed_description>This open , unblinded non-randomized biological assay . Tehe study design slight modification recommendation propose Nordic Guidelines . Four concentration Artemisia vulgaris allergen extract , together positive negative control , use 10 mg/ml histamine dihydrochloride solution glycerinated phenol saline solution , respectively , test every patient duplicate volar surface forearm .</detailed_description>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>Positive clinical history inhalatory allergy Artemisia vulgaris . Subject provide write informed consent , appropriately sign date subject . Subject male female race ethinic group . Age major equal 18 year ninor equal 60 year study inclusion day . A positive prick test standardize commercially Artemisia vulgaris allergen extract ( Wheal medium diameter ≤ 3mm wheal area ≥ 7 mm2 ) . The skin prick test result valid perform within one year prior inclusion subject study . A positive test specific IgE Artemisia vulgaris ( CAPRAST major equal 2 ) . IgE result valid perform within one year prior inclusion subject study . Allergy symptom Artemisia vulgaris pollen season . Immunotherapy past 5 year allergen extract Artemisia vulgaris allergen extract may interfere allergene test ( example : Helianthus annuus ( sunflower ) elatior Ambrosia eiator ( ambrosia ) peach . Use drug may interfere skin reaction ( example : antihistamine ) . Treatment follow medication : oral tricyclic tetracyclic antidepressant , betablockers , corticosteroid ( major 10 mg/daily prednisone equivalent ) . Women pregnant breastfeeding period woman positive pregnancy test Visit 2 , skin prick test . Dermographism affect skin area test site either study visit . Atopic dermatitis affect skin area test site either study visit . Urticaria affect skin area test site either study visit . Diseases immune system relevant clinically , autoimmune immunodeficiency . Serious disease control may increase risk safety subject involve study , include , limited following : heart failure , uncontrolled severe respiratory disease , endocrine disease , clinically relevant kidney liver diseases hematological disease . Participation clinical trial within 30 day ( 5 time biological halflife research study product , whichever long ) prior inclusion subject clinical trial . Patients diseases condition limit use adrenaline . Severe psychiatric , psychological neurological disorder . Abuse alcohol , drug medicine previous year . Subjects receive antiIgE ( Omalizumab ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Pollen</keyword>
</DOC>